CINECA IRIS Institutional Research Information System

LOLLI, Marco Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.748
EU - Europa 4.752
AS - Asia 1.839
AF - Africa 68
SA - Sud America 57
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 8
Totale 12.494
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.576
IT - Italia 1.872
CN - Cina 653
IE - Irlanda 540
DE - Germania 474
SE - Svezia 441
SG - Singapore 408
GB - Regno Unito 292
FR - Francia 259
UA - Ucraina 203
IN - India 160
CA - Canada 157
AT - Austria 156
VN - Vietnam 154
FI - Finlandia 145
KR - Corea 85
ID - Indonesia 74
JP - Giappone 74
HK - Hong Kong 64
PL - Polonia 61
DK - Danimarca 50
BE - Belgio 47
NL - Olanda 34
RO - Romania 32
TW - Taiwan 31
IR - Iran 30
BR - Brasile 29
SN - Senegal 26
AU - Australia 22
ES - Italia 22
CZ - Repubblica Ceca 20
PK - Pakistan 18
RU - Federazione Russa 18
TR - Turchia 18
NG - Nigeria 17
PT - Portogallo 15
CH - Svizzera 14
GR - Grecia 14
CO - Colombia 13
MY - Malesia 13
SA - Arabia Saudita 10
MX - Messico 9
AR - Argentina 8
EU - Europa 8
ZA - Sudafrica 7
CI - Costa d'Avorio 6
HR - Croazia 6
IQ - Iraq 6
JO - Giordania 6
SI - Slovenia 6
TH - Thailandia 6
UZ - Uzbekistan 6
BG - Bulgaria 5
BZ - Belize 5
MA - Marocco 5
NO - Norvegia 5
PH - Filippine 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
EG - Egitto 4
MO - Macao, regione amministrativa speciale della Cina 4
CY - Cipro 3
IL - Israele 3
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
LU - Lussemburgo 2
MK - Macedonia 2
MT - Malta 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BO - Bolivia 1
CU - Cuba 1
EE - Estonia 1
LV - Lettonia 1
SY - Repubblica araba siriana 1
TG - Togo 1
Totale 12.494
Salva come PNG Salva come JPEG
Città #
Chandler 820
Dublin 533
Torino 358
Ann Arbor 327
Singapore 307
Fairfield 289
Beijing 281
Turin 243
Houston 241
Nyköping 220
Ashburn 212
Woodbridge 207
Jacksonville 201
Vienna 155
Wilmington 151
Medford 140
Seattle 137
Princeton 127
Dong Ket 123
Los Angeles 121
Villeurbanne 118
Dearborn 117
Frankfurt am Main 109
Redwood City 108
Cambridge 107
Milan 94
Pisa 85
Fremont 76
Jakarta 70
Rome 62
Ottawa 58
Munich 53
Santa Clara 51
Warsaw 49
Boston 47
Guangzhou 47
Nanjing 46
Shanghai 38
Brussels 37
Copenhagen 35
New York 31
Toronto 30
Boardman 29
Hangzhou 27
Horia 26
Washington 25
San Diego 23
Hefei 21
Norwalk 21
Québec 21
Helsinki 20
Tokyo 19
Paris 16
Delhi 15
Naples 15
Taipei 15
Abuja 14
Chengdu 14
Piemonte 14
Lappeenranta 13
Menlo Park 13
Padova 13
Rivoli 13
Viterbo 13
Bradford 12
Buffalo 12
Central 12
Leinì 12
Pittsburgh 12
Verona 12
West Jordan 12
Ahmedabad 11
Florence 11
Modena 11
Ypsilanti 11
Amsterdam 10
Bari 10
Braunschweig 10
Leeds 10
Gunzenhausen 9
Hebei 9
Jinan 9
Kuala Lumpur 9
Mountain View 9
Mumbai 9
Phoenix 9
Pune 9
Siena 9
Taichung 9
Tianjin 9
Alpignano 8
Birmingham 8
Catanzaro 8
Chennai 8
Chicago 8
Duncan 8
Falls Church 8
Genoa 8
Hamburg 8
Hong Kong 8
Totale 7.408
Salva come PNG Salva come JPEG
Nome #
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 517
1,2,5-Oxadiazole analogues of leflunomide and related compounds 436
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 348
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 313
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 283
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 246
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold 241
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 228
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 195
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 187
Multiple catalytic activities of human 17β-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors. 175
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 171
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 167
The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors 160
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 157
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 156
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 153
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 152
Recent advances in the synthesis of analogues of phytohormones strigolactones with ring-closing metathesis as a key step 152
A novel SWCNT platform bearing DOTA and b-cyclodextrin units. "One shot" multidecoration under microwave irradiation. 147
Structure Activity Relationship of strigolactones via a novel, quantitative in planta bioassay 142
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 139
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 139
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 129
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 127
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 121
PROBING THE BICYCLIC HYDROXYPYRAZOLO[1,5-a]PYRIDINE SCAFFOLD AS A CARBOXYLIC ACID BIOISOSTERE IN THE GABAa RECEPTOR SYSTEM 121
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells 117
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 117
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 115
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 113
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 111
4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site 111
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 108
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 107
SAR STUDIES ON H2 ANTAGONISTS CONTAINING ALKYLAMINO SUBSTITUTED 1,2,5-THIADIAZOLE 1-OXIDE MOIETIES 105
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 104
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity 104
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 103
ONE -POT ALKOXYMERCURATION-BROMODEMERCURIATION: A VERSATILE ACCESS TO 3-ALKOXY-2-BROMOPROPANOIC ESTERS 102
Inibitori della diidroorotato deidrogenasi umana (hDHODH) per l'uso come antivirali 99
A new class of ibuprofen derivatives with reduced gastrotoxicity 98
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 98
Application of the arachno™ technology inside Educational fields: the introduction of parallel synthesis concepts inside an undergraduated lab 97
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds 93
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 93
APPLICATION OF THE ARACHNO™ TECHNOLOGY FOR THE PARALLEL SYNTHESIS OF A LIBRARY OF ASPIRIN ANALOGUES 92
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 91
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 91
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 88
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 85
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 84
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 84
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 83
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 82
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 80
Discovery of new NIK inhibitors by Structure-Based Drug Design 79
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin 78
Unsymmetrically substituted furoxants. 17. Structural investigations in benzenesulfonylfuroxan derivatives and related compounds 77
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 77
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 76
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 76
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 74
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 72
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 72
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 71
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 70
Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters 68
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 67
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 67
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 66
Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans) 65
Probing the bicyclic hydroxypyrazolo[1,5-a]pyridine scaffold as a carboxylic acid bioisostere in theGABAA receptor system 63
Synthesis of new Gadolinium complexes for magnetic resonance imaging with improved relaxivity 63
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 63
Synthesis of labelled [N-15(3)]-6-bromopurine, a useful precursor of N-15-labelled O-6-alkylguanines, to be used as internal standards for quantitative GC-MS analyses 62
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 60
Probing salicylamide bioisosteric replacement in the design of Plasmodium Falciparum dihydroorotate dehydrogenase (pfDHODH) inhibitors 59
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 59
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 59
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL AMINO BIOISOSTERES FOR THE GABAa RECEPTOR 58
Synthesis of new Plasmodium Falciparum dihydroorotate dehydrogenase inhibitors through the application of an isosteric portfolio 57
Synthesis of new gadolinium complexes for magnetic resonance imaging with improved relaxivity 57
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 57
Uses of the 4-hydroxy-1,2,5-oxadiazole-3-yl mojety as novel bioisoster of the carboxyl group 54
Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of selective ligands for subtypes AMPA receptor 54
Hydroxypyrazolo[1,5-a]pyridine as a fluorescent carboxylic acid isostere: introducing GABAA receptor system affinities in the scaffold 53
NEW CLASS OF NO-DONORS WITH BONE SELECTIVITY 52
Synthesis of NO-Donor Bisphosphonates and Their in Vitro Action on Bone Resorption 52
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 52
The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses [Calistri A.*, Luganini A.*, co-first author] 52
Detection of O6-Butylguanine and O6-(4-Hydroxybutyl)guanine in Urothelial and Hepatic DNA of Rats Given the Bladder Cancerogen N-Nitrosobutyl-(4-hydroxybutyl)amine 51
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 50
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 50
New NO-donor Bisphosphonates 49
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 49
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 49
Urinary Excretion of O6-Butylguanine after the Administration of N-Nitroso-N-butylurea in Rats 48
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 48
Totale 11.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.241
article - articoli 0
book - libri 0
conference - conferenze 19.942
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.183
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.295 0 0 0 162 90 238 195 106 143 148 118 95
2020/20211.461 140 126 87 81 103 62 105 74 229 97 132 225
2021/20221.816 76 60 115 169 84 70 103 86 39 215 468 331
2022/20232.990 288 328 109 290 215 668 260 198 252 90 167 125
2023/20241.744 205 212 114 87 121 189 190 80 25 159 137 225
2024/2025841 116 298 309 118 0 0 0 0 0 0 0 0
Totale 12.918